Frequently Asked Questions
The market is segmented based on , By Diagnosis (Imaging, Biopsy, Others), Type (ACXT-3102, AL-3818, Axitinib, CMB-305, CUE-102, Others), Treatment (Surgery, Anti-Angiogenesis, Drugs Radiation Therapy, Chemotherapy), End-Users (Hospitals, Specialty Clinics, Oncology Centers, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) – Industry Trends and Forecast to 2030.
.
The Global Synovial Sarcoma Treatment Market size was valued at USD 38.50 USD Billion in 2022.
The Global Synovial Sarcoma Treatment Market is projected to grow at a CAGR of 5% during the forecast period of 2023 to 2030.
The major players operating in the market include F. Hoffmann La Roche Ltd, Bayer AG, Epizyme, Cue Biopharma, Eli Lilly and Company, Adaptimmune Therapeutics Plc, Advenchen Laboratories LLC, EpiZyme , Merck & Co. , Immunocore Ltd, Johnson & Johnson Private Limited, Karyopharm Therapeutics , Novartis AG, Pfizer , Takara Bio .
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
